CDC Endorses Boosters for Moderna and J&J Vaccines

October 22, 2021

Last night, the CDC endorsed the Advisory Committee on Immunization Practices’ (ACIP) recommendation in favor of booster doses for the Moderna and Johnson & Johnson (J&J) vaccines. The Moderna vaccine has been endorsed for use as a booster vaccine (at least 6 months after the primary series) in the following populations:

  • those 65+ years in age
  • those 18+in long-term care settings
  • those 18+ who have certain underlying medical conditions
  • those 18+ who work or live in high-risk settings

The J&J vaccine has been recommended for persons 18+ years of age, 2 months after their primary dose.

Unlike the Moderna booster (which is a half dose at 50 micrograms), Pfizer and J&J booster doses will measure the same as the primary series. Those who are immunocompromised and completing a primary series as well as an additional dose, are recommended to utilize vaccines from the same manufacturer. Those who are “moderately to severely” immunocompromised and received a J&J primary series, should receive a 50 microgram dose of the Moderna vaccine should they decide to mix-and-match between the primary series and booster. Those who receive a third, 100 microgram dose of the Moderna vaccine due to their immunocompromised status, should not get a 4th booster shot from Pfizer or J&J at this time (1).

It was emphasized that those who completed a primary series of COVID-19 vaccination are still considered fully immunized. The Moderna and J&J vaccines have been shown to remain protective with only a slight decline in efficacy over time.

Join Our Community!Stay Informed. Stay Hopeful.

Sign up for periodic emails with resources, insights, and updates on autoimmune disease and living with chronic illness.

By adding your phone number, you agree to receive text message updates. Msg & data rates may apply.